November 22, 2016 - By Linda Rogers · 0 Comments
Recro Pharma (NASDAQ:REPH) institutional sentiment increased to 2.22 in Q2 2016. Its up 0.42, from 1.8 in 2016Q1. The ratio has increased, as 9 hedge funds increased and started new equity positions, while 5 cut down and sold their holdings in Recro Pharma. The hedge funds in our partner’s database now own: 3.87 million shares, down from 3.89 million shares in 2016Q1. Also, the number of hedge funds holding Recro Pharma in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 4 Increased: 5 New Position: 4.
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $102.09 million. The Firm is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. It currently has negative earnings. The Company’s lead product candidate is an injectable form of meloxicam.
The stock decreased 0.47% or $0.04 on November 21, hitting $8.53. Recro Pharma Inc (NASDAQ:REPH) has risen 21.16% since April 20, 2016 and is uptrending. It has outperformed by 16.61% the S&P500.
According to Zacks Investment Research, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.”
Broadfin Capital Llc holds 1.59% of its portfolio in Recro Pharma Inc for 2.06 million shares. Cormorant Asset Management Llc owns 778,288 shares or 0.88% of their US portfolio. Moreover, Tourbillon Capital Partners L.P. has 0.1% invested in the company for 646,552 shares. The New York-based Spark Investment Management Llc has invested 0.03% in the stock. Bb&T Corp, a North Carolina-based fund reported 50,000 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 2 insider purchases, and 0 sales for $2.99 million net activity.
Ratings analysis reveals 100% of Recro Pharma’s analysts are positive. Out of 6 Wall Street analysts rating Recro Pharma, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $14 while the high is $21. The stock’s average target of $17.50 is 105.16% above today’s ($8.53) share price. REPH was included in 8 notes of analysts from August 25, 2015. The firm has “Hold” rating by Zacks given on Tuesday, August 25. The firm earned “Buy” rating on Tuesday, November 24 by H.C. Wainwright. The firm has “Buy” rating by Janney Capital given on Monday, August 29. The firm earned “Buy” rating on Monday, November 14 by Aegis Capital. TH Capital initiated the stock with “Buy” rating in Friday, September 16 report. The rating was initiated by Roth Capital with “Buy” on Friday, September 16. The firm has “Buy” rating given on Monday, October 3 by Brean Capital. The rating was initiated by H.C. Wainwright on Wednesday, September 2 with “Buy”.
Recro Pharma, Inc., incorporated on November 15, 2007, is a clinical-stage specialty pharmaceutical company. The Firm is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. The Company’s product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. The Company’s manufacturing and development capabilities include formulation through process development, scale-up and full-scale commercial manufacturing and specialized capabilities for the development and manufacturing of controlled substances.
Another recent and important Recro Pharma Inc (NASDAQ:REPH) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on March 10, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers